Commentary

Dear Mr. Morgenthaler,

Thank you for the “Health & Wellness Update.” I look forward to each issue, and the solid information it provides.

Praise for
Smart Publications
Health & Wellness Update

"For sometime now I have enjoyed reading Smart Publications. They are beautifully structured, well written and educational"

"Wealth of information for anyone that chooses alternative healing methods. It's an education in itself just to read one of these newsletters! Every time I get one I read it from cover to cover! Easy to understand and easy to decipher when looking for products. Well done! It's a joy to read."

Smart Drugs & Nutrients:

How to Improve Your Memory and Increase Your Intelligence Using the Latest Discoveries In Neuroscience

VOLUME 1 in the Smart Drugs Series

by Ward Dean, M.D. & John Morgenthaler
$12.95 - 224 pages, softcover (Out of Stock)

• Table of Contents
• Previous Section
• Next Section
  

Appendix F:
FDA Drug Bulletin

The appropriateness or the legality of prescribing approved drugs for uses not included in their official labeling is sometimes a cause of concern and confusion among practitioners.

Under the federal Food, Drug, and Cosmetic (FD&C) Act, a drug approved for marketing may be labeled, promoted, and advertised by the manufacturer only for those uses for which the drug's safety and effectiveness have been established and which the FDA has approved. These are commonly referred to as "approved uses". This means that adequate and well‑controlled clinical trials have documented these uses, and the results of the trials have been reviewed and approved by the FDA.

The FD&C Act does not, however, limit the manner in which a physician may use an approved drug. Once a product has been approved for marketing, a physician may prescribe it for uses or in treatment regimens or patient populations that are not included in approved labeling. Such "unapproved" uses may be appropriate and rational in certain circumstances, and may, in fact, reflect approaches to drug therapy that have been extensively reported in medical literature.

The term "unapproved uses" is, to some extent, misleading. It includes a variety of situations ranging from unstudied to thoroughly investigated drug uses. Valid new uses for drugs already on the market are often first discovered through serendipitous observations and therapeutic innovations, subsequently confirmed by well‑planned and executed clinical investigation. Before such advances can be added to the approved labeling, however, data substantiating the effective­ness of a new use or regimen must be submitted by the manufacturer to the FDA for evaluation. This may take time and, without the initiative of the drug manufacturer whose product is involved, may never occur. For that reason, accepted medical practice often includes drug use that is not reflected in approved drug labeling.

With respect to its role in medical practice, the package insert is informational only. The FDA tries to assure that prescription drug information in the package insert accurately and fully reflects the data on safety and effectiveness on which drug approval is based.